Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16110696 | 0.87 | MAPK1 (1.00) | MAPK1 | |
| SCHEMBL14908278 | 0.87 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL14908033 | 0.85 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL14895761 | 0.85 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL14895763 | 0.85 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL16133868 | 0.85 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL16133926 | 0.84 | MAPK1 (1.00) | MAPK1 | |
| SCHEMBL14908131 | 0.84 | MAPK1 (0.84) | MAPK1 | |
| SCHEMBL14908047 | 0.84 | MAPK1 (1.00) | MAPK1 | |
| SCHEMBL16137151 | 0.84 | MAPK1 (1.00) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023865-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | claimed |
| EP-2770987-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2770987-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9023865-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023865-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140296203-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296203-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296203-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | MAPK1 1/4885CYP3A4 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.